Short Interest in Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Decreases By 30.0%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPIGet Rating) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 94,900 shares, a decline of 30.0% from the April 30th total of 135,600 shares. Based on an average daily trading volume, of 1,590,000 shares, the days-to-cover ratio is currently 0.1 days.

Several hedge funds have recently made changes to their positions in PTPI. Northern Trust Corp purchased a new position in shares of Petros Pharmaceuticals in the fourth quarter valued at $46,000. Squarepoint Ops LLC purchased a new position in shares of Petros Pharmaceuticals in the fourth quarter valued at $119,000. State Street Corp purchased a new position in shares of Petros Pharmaceuticals in the fourth quarter valued at $149,000. Virtu Financial LLC purchased a new position in shares of Petros Pharmaceuticals in the fourth quarter valued at $177,000. Finally, Geode Capital Management LLC boosted its stake in shares of Petros Pharmaceuticals by 147.8% in the fourth quarter. Geode Capital Management LLC now owns 58,785 shares of the company’s stock valued at $195,000 after purchasing an additional 35,060 shares during the period. Institutional investors and hedge funds own 6.08% of the company’s stock.

Shares of PTPI stock opened at $0.94 on Friday. The company has a market capitalization of $19.46 million, a PE ratio of -0.82 and a beta of 1.80. The firm has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $1.78. The company has a current ratio of 2.61, a quick ratio of 0.97 and a debt-to-equity ratio of 0.27. Petros Pharmaceuticals has a twelve month low of $0.65 and a twelve month high of $5.20.

Petros Pharmaceuticals (NASDAQ:PTPIGet Rating) last announced its earnings results on Friday, April 1st. The company reported ($0.72) earnings per share for the quarter. The firm had revenue of ($0.87) million during the quarter. Petros Pharmaceuticals had a negative net margin of 53.76% and a negative return on equity of 52.48%.

Petros Pharmaceuticals Company Profile (Get Rating)

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease.

Further Reading

Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.